A randomized, open-label, multicentric parallel group study to assess the impact of supportive measures on the drug adherence of patients with essential hypertension treated with valsartan or valsartan plus HCTZ for 34 weeks with or without respective measures

Trial Profile

A randomized, open-label, multicentric parallel group study to assess the impact of supportive measures on the drug adherence of patients with essential hypertension treated with valsartan or valsartan plus HCTZ for 34 weeks with or without respective measures

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Valsartan (Primary) ; Valsartan/hydrochlorothiazide (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms VALIDATE
  • Sponsors Novartis
  • Most Recent Events

    • 07 Nov 2011 Additional location (Germany) added as reported by ClinicalTrials.gov.
    • 07 Nov 2011 Actual end date (June 2007) added as reported by ClinicalTrials.gov.
    • 07 Nov 2007 Status changed from in progress to completed
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top